This content is only available within our institutional offering.
07 May 2020
NOVO NORDISK: Long-term outlook is still brighter than short-term one | NEUTRAL | DKK390 vs. DKK380 (-9%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
NOVO NORDISK: Long-term outlook is still brighter than short-term one | NEUTRAL | DKK390 vs. DKK380 (-9%)
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
07 May 2020 -
Author:
Eric Le Berrigaud -
Pages:
3
NOVO NORDISK - NEUTRAL | DKK390 vs. DKK380 (-9%)
Long-term outlook is still brighter than short-term one
Underlying trends are quite different from what Q1 showed
Semaglutide in NASH was the focus during the call
Our FV is modestly adjusted, NEUTRAL reiterated